Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258593 | 0.92 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA | |
| SCHEMBL15690548 | 0.84 | ALDH1A1 (0.42) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA | |
| SCHEMBL629503 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA | |
| SCHEMBL30775025 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA | |
| SCHEMBL28258845 | 0.79 | KDM4E (0.48) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA | |
| SCHEMBL1258994 | 0.77 | ALDH1A1 (0.63) | ALDH1A1PDGFRBPDGFRAMAPTCYP11B1 | |
| SCHEMBL30775085 | 0.77 | ALDH1A1 (0.63) | ALDH1A1PDGFRBPDGFRAMAPTCYP11B1 | |
| SCHEMBL621588 | 0.76 | KDM4E (0.55) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA | |
| SCHEMBL19674039 | 0.76 | KMT2A (0.48) | KDM4EKMT2APDGFRBPDGFRABACE1 | |
| SCHEMBL1812912 | 0.76 | KDM4E (0.46) | ALDH1A1KDM4EKMT2APDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107072985-B | Therapeutic inhibiting compounds | 莱福斯希医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| CN-102361863-A | Novel bicyclic antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-22 | — | — | CN | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ALDH1A1 1717/4885KDM4E 798/4885KMT2A 1049/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ALDH1A1 1717/4885KDM4E 798/4885KMT2A 1049/4885 |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | ALDH1A1 4235/4885KDM4E 3573/4885KMT2A 3611/4885 |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | ALDH1A1 421/4885KDM4E 4022/4885KMT2A 4612/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | ALDH1A1 1717/4885KDM4E 798/4885KMT2A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.